ArticleJournal of the International AIDS Society2026
Mpox Vaccination and Diagnosis Among Sexual and Gender Diverse Populations in Brazil: Results From a Large Nationwide Online Survey.
Article in Journal of the International AIDS Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Towards Elimination of Sexually Transmitted Infections: Research Developments and Vaccine Uptake.Journal of the International AIDS Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionSince the onset of the 2022 multinational mpox outbreak, Brazil has reported one of the highest case burdens globally, disproportionately affecting sexual and gender diverse populations. Mpox vaccination efforts in Brazil have been limited by delayed procurement, restricted eligibility criteria and structural access barriers. Understanding vaccination use, correlates of uptake and characteristics of individuals previously diagnosed with mpox is essential to guide equitable prevention strategies.
methodsWe conducted an online cross-sectional survey between August and December 2024 among individuals recruited through social media and dating apps. Eligible participants were aged ≥18 years, identified as a sexual and gender diverse person, and residing in Brazil. Primary outcomes were previous mpox vaccination and mpox diagnosis. Sociodemographic, behavioural, internalized LGBTQIAPN+phobia and HIV/sexually transmitted infections (STIs) variables were collected. Adjusted logistic regression models identified independent factors associated with both outcomes.
resultsOf 9546 respondents, most were cisgender men (91.8%), aged >30 years (81.5%) and residing in capital cities (77.2%). Overall, mpox vaccination coverage was 4.9%; nearly half received only one dose, and one quarter were vaccinated outside Brazil. Previous mpox diagnosis was reported by 2.1% of respondents, with 76.5% seeking healthcare and 7.0% requiring hospitalization. Factors associated with previous mpox vaccination were self-identification as White (aOR = 1.36; 95% CI: 1.10-1.69), more than five sex partners (aOR = 1.29; 95% CI: 1.03-1.62), living with HIV (aOR = 3.40; 95% CI: 2.59-4.47), current/prior HIV pre-exposure prophylaxis (PrEP) use (aOR = 1.88; 95% CI: 1.41-2.53) and internalized LGBTQIAPN+phobia score (aOR = 0.80; 95% CI: 0.71-0.90). Factors associated with previous mpox diagnosis were living in capital cities (aOR = 1.88; 95% CI: 1.17-3.20), more than five sex partners (aOR = 1.93; 95% CI: 1.35-2.79), stimulant drug use (aOR = 1.61; 95% CI: 1.14-2.25), any STI diagnosis (aOR = 2.41; 95% CI: 1.74-3.33), living with HIV (aOR = 3.73; 95% CI: 2.31-6.25) and current/prior PrEP use (aOR = 2.35; 95% CI: 1.43-4.01).
conclusionsMpox vaccination among sexual and gender diverse populations in Brazil remains critically low. Findings highlight structural barriers, including vaccine scarcity, delayed rollout and stigma, that hinder equitable vaccine access. Integrating mpox vaccination into combined HIV/STI prevention services, adopting differentiated care delivery models and partnering with community-led organizations are essential to expanding reach, improving dose completion and reducing health inequities during ongoing and future outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.